• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经母细胞瘤相关基因变异的研究进展

Research progress of neuroblastoma related gene variations.

作者信息

Cao Yanna, Jin Yan, Yu Jinpu, Wang Jingfu, Yan Jie, Zhao Qiang

机构信息

Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, P.R. China.

Department of Cancer Molecular Diagnostic Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, P.R. China.

出版信息

Oncotarget. 2017 Mar 14;8(11):18444-18455. doi: 10.18632/oncotarget.14408.

DOI:10.18632/oncotarget.14408
PMID:28055978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5392342/
Abstract

Neuroblastoma, the most common extracranial solid tumor among children, is an embryonal tumor originating from undifferentiated neural crest cell. Neuroblastomas are highly heterogeneous, represented by the wide range of clinical presentations and likelihood of cure, ranging from spontaneous regression to relentless progression despite rigorous multimodal treatments. Approximately, 50% of cases are high-risk with overall survival rates less than 40%. With the efforts to collect large numbers of clinically annotated specimens and the advancements in technologies, researchers have revealed numerous genetic alterations that may drive tumor growth. However, the most lack mutations in genes that are recurrently mutated, which inspires researchers to identify disrupted pathways instead of single mutated genes to unearth biological systems perturbed in neuroblastoma. Stratification of patients and target therapy based on their molecular signatures have been the center of focus. This review provides a comprehensive summary of the recent advances in identification of candidate genes variations, targeted approaches to high-risk neuroblastoma and evaluates the methods utilized for detection, which will provide new avenues to develop therapies and further genetic researches.

摘要

神经母细胞瘤是儿童最常见的颅外实体瘤,是一种起源于未分化神经嵴细胞的胚胎性肿瘤。神经母细胞瘤具有高度异质性,临床表现和治愈可能性差异很大,从自发消退到尽管进行了严格的多模式治疗仍无情进展。大约50%的病例为高危,总体生存率低于40%。随着收集大量临床注释标本的努力以及技术的进步,研究人员已经揭示了许多可能驱动肿瘤生长的基因改变。然而,最缺乏的是反复突变基因中的突变,这促使研究人员识别被破坏的通路而非单个突变基因,以挖掘神经母细胞瘤中受到干扰的生物系统。基于患者分子特征的分层和靶向治疗一直是关注的焦点。本综述全面总结了候选基因变异鉴定、高危神经母细胞瘤靶向治疗方法的最新进展,并评估了所使用的检测方法,这将为开发治疗方法和进一步的基因研究提供新途径。

相似文献

1
Research progress of neuroblastoma related gene variations.神经母细胞瘤相关基因变异的研究进展
Oncotarget. 2017 Mar 14;8(11):18444-18455. doi: 10.18632/oncotarget.14408.
2
Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.临床侵袭性神经母细胞瘤的外显子组和深度测序揭示了影响癌症进展相关关键通路的体细胞突变。
Oncotarget. 2016 Apr 19;7(16):21840-52. doi: 10.18632/oncotarget.8187.
3
BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.BLM种系和体细胞PKMYT1及AHCY突变:神经母细胞瘤中除MYCN之外的基因变异与预后
Med Hypotheses. 2016 Dec;97:22-25. doi: 10.1016/j.mehy.2016.10.008. Epub 2016 Oct 20.
4
Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.靶向下一代测序检测到的遗传改变及其在神经母细胞瘤中的临床意义。
Anticancer Res. 2020 Dec;40(12):7057-7065. doi: 10.21873/anticanres.14733.
5
The biologic basis for neuroblastoma heterogeneity and risk stratification.神经母细胞瘤异质性和风险分层的生物学基础。
Curr Opin Pediatr. 2005 Feb;17(1):7-13. doi: 10.1097/01.mop.0000150631.60571.89.
6
Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.神经母细胞瘤的近期生物学和遗传学进展:对诊断、风险分层及治疗策略的影响
Semin Pediatr Surg. 2016 Oct;25(5):257-264. doi: 10.1053/j.sempedsurg.2016.09.007. Epub 2016 Sep 28.
7
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.神经母细胞瘤中ALK激酶受体的体细胞和生殖系激活突变。
Nature. 2008 Oct 16;455(7215):967-70. doi: 10.1038/nature07398.
8
Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma.神经母细胞瘤中胚系和体细胞基因组改变认识的进展
Cancer Genet. 2011 Mar;204(3):113-21. doi: 10.1016/j.cancergen.2011.03.001.
9
Recent insights into the biology of neuroblastoma.近期对神经母细胞瘤生物学的见解。
Int J Cancer. 2014 Nov 15;135(10):2249-61. doi: 10.1002/ijc.29077. Epub 2014 Aug 14.
10
Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.用于治疗神经母细胞瘤的处于II期临床试验阶段的研究性药物。
Expert Opin Investig Drugs. 2017 Nov;26(11):1281-1293. doi: 10.1080/13543784.2017.1380625. Epub 2017 Sep 26.

引用本文的文献

1
The Effect of MicroRNA 21 and MicroRNA 200b Expression on Carcinogenesis in Endometriosis-Associated Ovarian Cancers and Relationship with Clinicopathological Parameters.微小RNA 21和微小RNA 200b表达对子宫内膜异位症相关卵巢癌发生的影响及其与临床病理参数的关系
Medicina (Kaunas). 2025 Jun 4;61(6):1035. doi: 10.3390/medicina61061035.
2
Prognostic factors for intermediate- or high-risk neuroblastomas in children in China.中国儿童中中高危神经母细胞瘤的预后因素。
BMC Pediatr. 2023 Dec 6;23(1):617. doi: 10.1186/s12887-023-04258-w.
3
A narrative review of radiomics and deep learning advances in neuroblastoma: updates and challenges.神经母细胞瘤放射组学和深度学习进展的叙述性综述:更新与挑战。
Pediatr Radiol. 2023 Dec;53(13):2742-2755. doi: 10.1007/s00247-023-05792-6. Epub 2023 Nov 10.
4
Negr1-Derived Peptides Trigger ALK Degradation and Halt Neuroblastoma Progression In Vitro and In Vivo.源自Negr1的肽在体外和体内触发间变性淋巴瘤激酶(ALK)降解并阻止神经母细胞瘤进展。
Pharmaceutics. 2023 Sep 12;15(9):2307. doi: 10.3390/pharmaceutics15092307.
5
Genomic Analysis Made It Possible to Identify Gene-Driver Alterations Covering the Time Window between Diagnosis of Neuroblastoma 4S and the Progression to Stage 4.基因组分析使得鉴定神经母细胞瘤 4S 诊断和进展至 4 期之间的时间窗内的基因驱动改变成为可能。
Int J Mol Sci. 2022 Jun 10;23(12):6513. doi: 10.3390/ijms23126513.
6
The Potential Role of Exosomes in the Treatment of Brain Tumors, Recent Updates and Advances.外泌体在脑肿瘤治疗中的潜在作用:最新进展
Front Oncol. 2022 Mar 17;12:869929. doi: 10.3389/fonc.2022.869929. eCollection 2022.
7
Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities.神经母细胞瘤中的生物标志物:对其潜在诊断和预后价值的深入了解。
Curr Treat Options Oncol. 2021 Sep 27;22(11):102. doi: 10.1007/s11864-021-00898-1.
8
Reporting Incidences of Neuroblastoma in Various Resource Settings.报告各种资源环境下神经母细胞瘤的发病情况。
JCO Glob Oncol. 2021 Jun;7:947-964. doi: 10.1200/GO.21.00054.
9
Management of neuroblastoma in limited-resource settings.资源有限环境下神经母细胞瘤的管理
World J Clin Oncol. 2020 Aug 24;11(8):629-643. doi: 10.5306/wjco.v11.i8.629.
10
An overview of neuroblastoma cell lineage phenotypes and models.神经母细胞瘤细胞谱系表型和模型概述。
Exp Biol Med (Maywood). 2020 Dec;245(18):1637-1647. doi: 10.1177/1535370220949237. Epub 2020 Aug 12.

本文引用的文献

1
Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma.磷酸化蛋白质组学揭示间变性淋巴瘤激酶通过RAS/ JNK信号通路促进神经母细胞瘤细胞进展。
Oncotarget. 2016 Nov 15;7(46):75968-75980. doi: 10.18632/oncotarget.12513.
2
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.第二代蛋白酶体抑制剂卡非佐米使神经母细胞瘤细胞对阿霉素诱导的凋亡敏感。
Oncotarget. 2016 Nov 15;7(46):75914-75925. doi: 10.18632/oncotarget.12427.
3
Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome.甘油磷酸二酯酶 GDE2 通过释放糖蛋白聚糖促进神经母细胞瘤分化,是临床预后的标志物。
Cancer Cell. 2016 Oct 10;30(4):548-562. doi: 10.1016/j.ccell.2016.08.016. Epub 2016 Sep 29.
4
Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.下一代测序揭示了一名同时患有肾母细胞瘤和神经母细胞瘤的婴儿的种系突变。
Pediatr Hematol Oncol. 2016 May;33(4):264-75. doi: 10.1080/08880018.2016.1184362.
5
Neuroblastoma: A Tough Nut to Crack.神经母细胞瘤:一块难啃的硬骨头。
Am Soc Clin Oncol Educ Book. 2016;35:e548-57. doi: 10.1200/EDBK_159169.
6
Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.临床侵袭性神经母细胞瘤的外显子组和深度测序揭示了影响癌症进展相关关键通路的体细胞突变。
Oncotarget. 2016 Apr 19;7(16):21840-52. doi: 10.18632/oncotarget.8187.
7
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.通过丝裂原活化蛋白激酶抑制剂靶向RAS信号通路。
Swiss Med Wkly. 2015 Dec 21;145:w14207. doi: 10.4414/smw.2015.14207. eCollection 2015.
8
Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.神经母细胞瘤患儿中MYCN蛋白和PI3K/AKT/mTOR信号通路的新型药效学生物标志物
Mol Oncol. 2016 Apr;10(4):538-52. doi: 10.1016/j.molonc.2015.11.005. Epub 2015 Nov 19.
9
Germline Mutations in Predisposition Genes in Pediatric Cancer.儿童癌症中易感基因的种系突变
N Engl J Med. 2015 Dec 10;373(24):2336-2346. doi: 10.1056/NEJMoa1508054. Epub 2015 Nov 18.
10
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.神经母细胞瘤转化基因组学的进展:从改善风险分层、揭示新生物学特性到识别可操作的基因组改变。
Cancer. 2016 Jan 1;122(1):20-33. doi: 10.1002/cncr.29706. Epub 2015 Nov 5.